Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | Senior Vice President | April 21, 2020 | April 24, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date April 21, 2020 · Filed April 24, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 62,205 |
Ending reported balance
After 2020-04-21 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2020-04-21 · Exercise / conversion · Acquired 46,016 · Balance 83,035 Row 2 · 2020-04-21 · Exercise / conversion · Acquired 36,715 · Balance 119,750 Row 3 · 2020-04-21 · Exercise / conversion · Acquired 25,681 · Balance 145,431 Row 4 · 2020-04-21 · Tax withholding · Disposed 83,226 · Balance 62,205 |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.40 · Expires 2027-02-16 | Direct | 0 |
Reported balance
After 2020-04-21 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-04-21 · Exercise / conversion · Disposed 46,016 · Balance 0 F5: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.94 · Expires 2028-02-15 | Direct | 36,715 |
Reported balance
After 2020-04-21 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2020-04-21 · Exercise / conversion · Disposed 36,715 · Balance 36,715 F6: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $75.90 · Expires 2029-02-21 | Direct | 51,364 |
Reported balance
After 2020-04-21 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2020-04-21 · Exercise / conversion · Disposed 25,681 · Balance 51,364 F6: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. |
| Common shares without par valueSEC Table I · non-derivative | IndirectProfit Sharing Trust | 22 |
Reported balance
Holding disclosure · report date 2020-04-21 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 22 F1: Balance in the Abbott Laboratories Stock Retirement Trust as of April 21, 2020. |
| Common shares without par valueSEC Table I · non-derivative | IndirectJaime Contreras Marvan 2006 Living Trust | 176,217 |
Reported balance
Holding disclosure · report date 2020-04-21 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 176,217 F2: Held in the Jaime Contreras Marvan 2006 Living Trust. The reporting person is sole trustee of the trust. The trust is revocable. |
| Common shares without par valueSEC Table I · non-derivative | IndirectBy Spouse | 2,624 |
Reported balance
Holding disclosure · report date 2020-04-21 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 2,624 F3: The reporting person disclaims beneficial ownership of all securities held by his spouse. |
| Common shares without par valueSEC Table I · non-derivative | IndirectLiving Trust (by spouse) | 12,081 |
Reported balance
Holding disclosure · report date 2020-04-21 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 12,081 F4: Held in spouse's living trust. The reporting person's spouse is sole trustee of the trust. The trust is revocable. The reporting person disclaims beneficial ownership of these securities. |
Filing footnotes · ownership attribution and instrument terms
F1: Balance in the Abbott Laboratories Stock Retirement Trust as of April 21, 2020.
F2: Held in the Jaime Contreras Marvan 2006 Living Trust. The reporting person is sole trustee of the trust. The trust is revocable.
F3: The reporting person disclaims beneficial ownership of all securities held by his spouse.
F4: Held in spouse's living trust. The reporting person's spouse is sole trustee of the trust. The trust is revocable. The reporting person disclaims beneficial ownership of these securities.
F5: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.
F6: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 29, 2018 Filed Aug 31, 2018 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 59,800 | $0.00 Strike: $34.94 | $0.00 |
DisclosureSEC source: 0001179110-18-011046 · edgar.xml · derivative · entry 31 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 59,800 shares Expires 2023-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,200 | $66.78 | $146,916.00 |
DisclosureSEC source: 0001179110-18-011046 · edgar.xml · nonDerivative · entry 30 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,111 Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 800 | $66.78 | $53,420.00 |
DisclosureSEC source: 0001179110-18-011046 · edgar.xml · nonDerivative · entry 29 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,311 Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 58,993 | $66.77 | $3,938,962.61 |
DisclosureSEC source: 0001179110-18-011046 · edgar.xml · nonDerivative · entry 28 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,111 Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 690 | $66.77 | $46,067.85 |
DisclosureSEC source: 0001179110-18-011046 · edgar.xml · nonDerivative · entry 27 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,104 Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,100 | $66.76 | $140,196.00 |
DisclosureSEC source: 0001179110-18-011046 · edgar.xml · nonDerivative · entry 26 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,794 Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $66.76 | $6,675.50 |
DisclosureSEC source: 0001179110-18-011046 · edgar.xml · nonDerivative · entry 25 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,894 Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,400 | $66.75 | $93,450.00 |
DisclosureSEC source: 0001179110-18-011046 · edgar.xml · nonDerivative · entry 24 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,994 Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,900 | $66.75 | $126,815.50 |
DisclosureSEC source: 0001179110-18-011046 · edgar.xml · nonDerivative · entry 23 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,394 Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,000 | $66.74 | $66,740.00 |
DisclosureSEC source: 0001179110-18-011046 · edgar.xml · nonDerivative · entry 22 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,294 Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 500 | $66.74 | $33,367.50 |
DisclosureSEC source: 0001179110-18-011046 · edgar.xml · nonDerivative · entry 21 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,294 Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,400 | $66.73 | $93,422.00 |
DisclosureSEC source: 0001179110-18-011046 · edgar.xml · nonDerivative · entry 20 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,794 Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,000 | $66.72 | $66,720.00 |
DisclosureSEC source: 0001179110-18-011046 · edgar.xml · nonDerivative · entry 19 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,194 Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,200 | $66.72 | $146,773.00 |
DisclosureSEC source: 0001179110-18-011046 · edgar.xml · nonDerivative · entry 18 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,194 Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 900 | $66.71 | $60,039.00 |
DisclosureSEC source: 0001179110-18-011046 · edgar.xml · nonDerivative · entry 17 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,394 Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 110 | $66.71 | $7,337.55 |
DisclosureSEC source: 0001179110-18-011046 · edgar.xml · nonDerivative · entry 16 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,294 Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,900 | $66.70 | $126,730.00 |
DisclosureSEC source: 0001179110-18-011046 · edgar.xml · nonDerivative · entry 15 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,404 Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 800 | $66.70 | $53,356.00 |
DisclosureSEC source: 0001179110-18-011046 · edgar.xml · nonDerivative · entry 14 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,304 Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 600 | $66.69 | $40,014.00 |
DisclosureSEC source: 0001179110-18-011046 · edgar.xml · nonDerivative · entry 13 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,104 Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,300 | $66.69 | $153,375.50 |
DisclosureSEC source: 0001179110-18-011046 · edgar.xml · nonDerivative · entry 12 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,704 Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,500 | $66.68 | $100,020.00 |
DisclosureSEC source: 0001179110-18-011046 · edgar.xml · nonDerivative · entry 11 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,004 Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,300 | $66.68 | $86,677.50 |
DisclosureSEC source: 0001179110-18-011046 · edgar.xml · nonDerivative · entry 10 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,504 Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 600 | $66.67 | $40,002.00 |
DisclosureSEC source: 0001179110-18-011046 · edgar.xml · nonDerivative · entry 9 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,804 Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,400 | $66.67 | $159,996.00 |
DisclosureSEC source: 0001179110-18-011046 · edgar.xml · nonDerivative · entry 8 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,404 Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,501 | $66.66 | $100,056.66 |
DisclosureSEC source: 0001179110-18-011046 · edgar.xml · nonDerivative · entry 7 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,804 Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,500 | $66.66 | $166,637.50 |
DisclosureSEC source: 0001179110-18-011046 · edgar.xml · nonDerivative · entry 6 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,305 Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,100 | $66.65 | $139,965.00 |
DisclosureSEC source: 0001179110-18-011046 · edgar.xml · nonDerivative · entry 5 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,805 Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 699 | $66.65 | $46,584.86 |
DisclosureSEC source: 0001179110-18-011046 · edgar.xml · nonDerivative · entry 4 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,905 Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,300 | $66.64 | $153,272.00 |
DisclosureSEC source: 0001179110-18-011046 · edgar.xml · nonDerivative · entry 3 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,604 Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 112,668 | $39.12 | $4,407,572.16 |
DisclosureSEC source: 0001179110-18-011046 · edgar.xml · nonDerivative · entry 2 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,904 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 59,800 | $34.94 | $2,089,412.00 |
DisclosureSEC source: 0001179110-18-011046 · edgar.xml · nonDerivative · entry 1 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,236 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 10,200 | $66.87 | $682,074.00 |
DisclosureSEC source: 0001179110-18-011047 · edgar.xml · nonDerivative · entry 17 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,968 F1 · balance_after: Excludes 7,875 shares previously directly owned which were transferred to the Jaime Contreras Marvan 2006 Living Trust on July 6, 2018. Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 474 | $66.87 | $31,694.01 |
DisclosureSEC source: 0001179110-18-011047 · edgar.xml · nonDerivative · entry 16 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,043 Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 14,800 | $66.86 | $989,528.00 |
DisclosureSEC source: 0001179110-18-011047 · edgar.xml · nonDerivative · entry 15 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,517 Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 840 | $66.86 | $56,158.20 |
DisclosureSEC source: 0001179110-18-011047 · edgar.xml · nonDerivative · entry 14 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,317 Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 8,335 | $66.85 | $557,194.75 |
DisclosureSEC source: 0001179110-18-011047 · edgar.xml · nonDerivative · entry 13 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,157 Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 805 | $66.85 | $53,810.23 |
DisclosureSEC source: 0001179110-18-011047 · edgar.xml · nonDerivative · entry 12 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,492 Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 4,116 | $66.84 | $275,113.44 |
DisclosureSEC source: 0001179110-18-011047 · edgar.xml · nonDerivative · entry 11 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,297 Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 928 | $66.84 | $62,022.88 |
DisclosureSEC source: 0001179110-18-011047 · edgar.xml · nonDerivative · entry 10 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,413 Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 200 | $66.83 | $13,365.00 |
DisclosureSEC source: 0001179110-18-011047 · edgar.xml · nonDerivative · entry 9 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,341 Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,799 | $66.82 | $120,209.18 |
DisclosureSEC source: 0001179110-18-011047 · edgar.xml · nonDerivative · entry 8 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,541 Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 600 | $66.82 | $40,089.00 |
DisclosureSEC source: 0001179110-18-011047 · edgar.xml · nonDerivative · entry 7 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,340 Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,900 | $66.81 | $193,749.00 |
DisclosureSEC source: 0001179110-18-011047 · edgar.xml · nonDerivative · entry 6 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,940 Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,463 | $66.81 | $164,540.72 |
DisclosureSEC source: 0001179110-18-011047 · edgar.xml · nonDerivative · entry 5 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,840 Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,505 | $66.80 | $167,334.00 |
DisclosureSEC source: 0001179110-18-011047 · edgar.xml · nonDerivative · entry 4 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,303 Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,768 | $66.80 | $184,888.56 |
DisclosureSEC source: 0001179110-18-011047 · edgar.xml · nonDerivative · entry 3 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,080 Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 8,895 | $66.79 | $594,097.05 |
DisclosureSEC source: 0001179110-18-011047 · edgar.xml · nonDerivative · entry 2 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,576 Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,640 | $66.79 | $109,527.40 |
DisclosureSEC source: 0001179110-18-011047 · edgar.xml · nonDerivative · entry 1 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,471 Read SEC document |
| April 23, 2018 Filed Apr 25, 2018 21:12 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 849 | $59.36 | $50,396.64 |
DisclosureSEC source: 0001179110-18-005873 · edgar.xml · nonDerivative · entry 4 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 2,595 F3 · balance_after: The reporting person disclaims beneficial ownership of all securities held by his spouse. Read SEC document |
| March 31, 2018 Filed Apr 3, 2018 22:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 342 | $59.92 | $20,492.64 |
DisclosureSEC source: 0001179110-18-005308 · edgar.xml · nonDerivative · entry 5 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 3,444 F4 · balance_after: The reporting person disclaims beneficial ownership of all securities held by his spouse. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.